FGF23对心脏的影响:水平、时间、来源与背景均重要
FGF23 effects on the heart-levels, time, source, and context matter.
PubMed 文献 · Kidney Int · 2018-01-01
成纤维细胞生长因子23(FGF23)在慢性肾脏病患者中显著升高。临床研究提示其与心脏病变及心血管死亡相关,而细胞与动物研究提示其可能直接导致心脏损伤,目前尚在 debate 中。
要点
- FGF23在CKD患者中大幅升高
- 临床研究显示FGF23与心脏病变和心血管死亡相关
- FGF23是否为心脏损伤的致病因素尚在争议中
核心结论
- FGF23是否为心血管疾病的危险因素或致病因素尚在辩论中,需考虑其水平、时间、来源与背景。
主要发现
- 临床研究提示FGF23与心脏病变及心血管死亡率相关。
- 细胞培养和动物研究提示FGF23可能直接导致心脏损伤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fibroblast growth factor 23 (FGF23) has appeared as a hormone that is massively elevated in patients with chronic kidney disease. Whether FGF23 is a risk factor that associates with cardiac pathologies and cardiovascular mortality, as suggested by a variety of clinical studies, or additionally acts as a causative factor that induces cardiac injury, as more recently indicated by cell culture and animal studies, is under debate and the center of many ongoing experimental studies.
来源:Kidney Int,查看原文。版权归原作者所有。
引用
- Faul C. FGF23 effects on the heart-levels, time, source, and context matter. Kidney Int. 2018. PMID: 29933856. doi:10.1016/j.kint.2018.03.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。